Menu
GWAS Study

Genome-wide association study of cardiac troponin I in the general population.

Moksnes MR, Røsjø H, Richmond A et al.

33961016 PubMed ID
GWAS Study Type
5178 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

MM
Moksnes MR
RH
Røsjø H
RA
Richmond A
LM
Lyngbakken MN
GS
Graham SE
HA
Hansen AF
WB
Wolford BN
GT
Gagliano Taliun SA
LJ
LeFaive J
RH
Rasheed H
TL
Thomas LF
ZW
Zhou W
AN
Aung N
SI
Surakka I
DN
Douville NJ
CA
Campbell A
PD
Porteous DJ
PS
Petersen SE
MP
Munroe PB
WP
Welsh P
SN
Sattar N
SG
Smith GD
FL
Fritsche LG
NJ
Nielsen JB
ÅB
Åsvold BO
HK
Hveem K
HC
Hayward C
WC
Willer CJ
BB
Brumpton BM
OT
Omland T
Chapter II

Abstract

Summary of the research findings

Circulating cardiac troponin proteins are associated with structural heart disease and predict incident cardiovascular disease in the general population. However, the genetic contribution to cardiac troponin I (cTnI) concentrations and its causal effect on cardiovascular phenotypes are unclear. We combine data from two large population-based studies, the Trøndelag Health Study and the Generation Scotland Scottish Family Health Study, and perform a genome-wide association study of high-sensitivity cTnI concentrations with 48 115 individuals. We further use two-sample Mendelian randomization to investigate the causal effects of circulating cTnI on acute myocardial infarction (AMI) and heart failure (HF). We identified 12 genetic loci (8 novel) associated with cTnI concentrations. Associated protein-altering variants highlighted putative functional genes: CAND2, HABP2, ANO5, APOH, FHOD3, TNFAIP2, KLKB1 and LMAN1. Phenome-wide association tests in 1688 phecodes and 83 continuous traits in UK Biobank showed associations between a genetic risk score for cTnI and cardiac arrhythmias, metabolic and anthropometric measures. Using two-sample Mendelian randomization, we confirmed the non-causal role of cTnI in AMI (5948 cases, 355 246 controls). We found indications for a causal role of cTnI in HF (47 309 cases and 930 014 controls), but this was not supported by secondary analyses using left ventricular mass as outcome (18 257 individuals). Our findings clarify the biology underlying the heritable contribution to circulating cTnI and support cTnI as a non-causal biomarker for AMI in the general population. Using genetically informed methods for causal inference helps inform the role and value of measuring cTnI in the general population.

5,178 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

5178
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.